Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BAY3498264 |
| Synonyms | |
| Therapy Description |
BAY3498264 inhibits the interaction of SOS1 and RAS, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4373). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BAY3498264 | BAY-3498264|BAY 3498264 | SOS1 Inhibitor 17 | BAY3498264 inhibits the interaction of SOS1 and RAS, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4373). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06659341 | Phase I | BAY3498264 | A Study to Learn BAY3498264 When Given Alone or Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation | Recruiting | ITA | GBR | ESP | DNK | AUS | 0 |